Year All20242023202220212020201920182017201620152014 2016 Full-Year Results and Progress Report March 15, 2017 Read More ABIVAX has discovered novel antiviral molecules with potential for Dengue virus treatment February 23, 2017 Read More ABIVAX to participate in RBC Capital Markets Global Healthcare Conference on February 22-23, 2017 in New York City February 16, 2017 Read More Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals February 02, 2017 Read More ABIVAX to receive €8.4 million from Bpifrance “Invest in the Future Program” (PIA) for the development of innovative antiviral drugs January 09, 2017 Read More ABIVAX to present at the Biotech Showcase™ Annual Conference in San Francisco January 04, 2017 Read More ABIVAX announces its financial calendar for 2017 December 19, 2016 Read More ABIVAX appoints Didier Blondel as Chief Financial Officer December 15, 2016 Read More ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544 December 12, 2016 Read More ABIVAX Reports New Preclinical Data Supporting ABX464 as HIV Functional Cure and Novel Treatment for Inflammatory Diseases at HIV DART Meeting December 08, 2016 Read More
ABIVAX has discovered novel antiviral molecules with potential for Dengue virus treatment February 23, 2017 Read More
ABIVAX to participate in RBC Capital Markets Global Healthcare Conference on February 22-23, 2017 in New York City February 16, 2017 Read More
Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals February 02, 2017 Read More
ABIVAX to receive €8.4 million from Bpifrance “Invest in the Future Program” (PIA) for the development of innovative antiviral drugs January 09, 2017 Read More
ABIVAX to present at the Biotech Showcase™ Annual Conference in San Francisco January 04, 2017 Read More
ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544 December 12, 2016 Read More
ABIVAX Reports New Preclinical Data Supporting ABX464 as HIV Functional Cure and Novel Treatment for Inflammatory Diseases at HIV DART Meeting December 08, 2016 Read More
